PPARγ also modifies ER signaling by promoting itsubiquitination and degradation [37] as well as by upregulating CYP19A1 (aromatase) activity [38, 39], which can blunt the activity of aromatase inhibitors usedto treat patients with ER+ breast cancer. This evidence concerns the gene PPARG and breast carcinoma.